Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

Trial Profile

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 31 May 2016

At a glance

  • Drugs Docosahexaenoic acid (Primary)
  • Indications Cognition disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 18 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 13 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top